Zeng Yuan

Dr. Zeng Yuan

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2013 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
YWYue Wang
Yue Wang
YWYiying Wang
Yiying Wang
JLJie Li
Jie Li
ZYZeng Yuan
Zeng Yuan
BYBingbing Yuan
Bingbing Yuan
WZWenxin Zheng
Wenxin Zheng
Background: Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it is difficult to make definitive diagnosis of presence of cancer cells, particularly gynecologic versus non-gynecologic origin, from those ascites specimens due to the absence of specific biomarkers of gynecologic cancers. In the present study, we evaluated if, in addition to the routine morphologic diagnosis, the biomarker PAX8 could be useful in recognition of ovarian epithelial cancer cells prior to the neoadjuvant chemotherapy. Methods: Two hundred and two cytology specimens including 120 pretreatment ovarian cancer samples, 60 benign controls, and 22 malignant non-gynecologic cases were studied. All cytology slides were morphologically reviewed in a blinded fashion without knowing corresponding pathology diagnosis, if present. A total of 168 cytology specimens with a cell block were stained with PAX8 and Calretinin. These included patients with potential for ovarian cancer neoadjuvant chemotherapy (n = 96), metastatic cancers (n = 22), and benign controls (n = 50). Results: Among the 96 ascitic samples prior to neoadjuvant chemotherapy, 76 (79%) showing morphologic features consistent with cancers of ovarian primary were all PAX+/Calretinin-. The remaining 20 (21%) cases were positive for adenocarcinoma, but morphologically unable to be further classified. Among the 22 metastatic cancers into the pelvis, one case with PAX8+/Calretinin- represented a renal cell carcinoma and the remaining 21 PAX8-/Calretinin- metastatic cancers were either breast metastasis (n = 4) and the metastasis from gastrointestinal tract (n = 17). Among the 50 benign control pelvic washing cases, 5 PAX8+/Calretinin-cases represented endosalpingiosis (n = 4) and endometriosis (n = 1), 25 PAX8-/Calretinin + cases showed reactive mesothelial cells, and the remaining 20 specimens with PAX8-/Calretinin- phenotype typically contained inflammatory or blood cells without noticeable diagnostic epithelia. Conclusions: PAX8 identifies all Müllerian derived benign or malignant epithelia. When combining with Calretinin, PAX8 is a sensitive marker to diagnose the carcinomas of ovarian origin, which will be ideal to be used for those patients with a possible advanced ovarian cancer prior to receiving neoadjuvant chemotherapy.

21 February 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CTChuangang Tang
Chuangang Tang
XHXiang Hu
Xiang Hu
DHDawei Hao
Dawei Hao
TCTao Chen
Tao Chen
PWPei Wang
Pei Wang
ZYZeng Yuan
Zeng Yuan
Background: Accumulating evidences suggested that immune checkpoints (ICPs) played an important role in malignancies including breast cancer (BRCA). We aimed to investigate whether inhibitory-to-stimulatory immune checkpoint ratio (ISICPR) could be used as a prognostic marker for BRCA.Methods: BRCA patients were enrolled from The Cancer Genome Atlas (TCGA). Survival analysis was performed with Kaplan-Meier (KM) methods. X-tile was used to calculate the optimal cut-off values of ISICPRs. Univariate and multivariate Cox regression analysis were carried out to identify prognostic factors for BRCA patients. Tissue microarray was used to validate our findings.Results: In total, 586 BRCA patients were collected, including 104 cases of stage I, 330 of stage II, 139 of stage III, and 13 of stage IV. Univariate analysis showed that four ISICPRs (PDCD1/CD27 ratio, PDCD1/TNFSF4 ratio, IDO1/TMIGD2 ratio, and IDO1/TNFSF4 ratio) were significantly associated with the survival of BRCA patients. After adjusting for confounders, multivariate analysis indicated that only the IDO1/TMIGD2 ratio was an independent prognostic factor. The optimal cut-off values for the IDO1/TMIGD2 ratio were set at 4.4 and 6.3. Survival analysis indicated that the high-ratio group (ratio > 6.3) had a worse prognosis than both the low-ratio (ratio < 4.4) and medium-ratio group (4.4 < ratio < 6.3) (P < 0.001), which was further validated by BRCA tissue microarray.Conclusions: We found that IDO1/TMIGD2 ratio was an independent prognostic factor for BRCA. On one hand, dual targeting of IDO1 and TMIGD2 may be a more effective therapeutic strategy for patients with a high IDO1/TMIGD2 ratio. On the other hand, ISICPR was a promising indicator with high clinical values and worthy of further promotion in other cancers.

28 October 2026 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
XXXinhua Xu
Xinhua Xu
XRXiaochen Ren
Xiaochen Ren
ZYZeng Yuan
Zeng Yuan
High-grade serous ovarian carcinoma (HGSOC) is marked by extensive genomic instability, characterized by near-universal TP53 mutations, frequent homologous recombination deficiency (HRD), widespread copy-number alterations, and complex structural rearrangements. However, much of our current understanding of this molecular landscape has been derived from exome sequencing, microarrays, and short-read whole-genome sequencing, which are limited in their ability to resolve repetitive and structurally complex genomic regions. Long-read sequencing, together with telomere-to-telomere reference assemblies, is beginning to reveal previously inaccessible aspects of HGSOC genome architecture. Exploratory studies have reported centromeric and transposable-element hypomethylation, chromosome-arm-specific telomere shortening, and complex extrachromosomal DNA (ecDNA) architectures associated with enhancer regulation and transposable-element activity. Complementary studies have also identified ongoing LINE-1 retrotransposition in HGSOC. Together, these observations suggest that repetitive DNA, epigenetic instability, and complex genome architecture may contribute to HGSOC heterogeneity and tumor evolution, although their causal relationships remain uncertain. Nevertheless, genome-wide long-read evidence in HGSOC currently derives primarily from two small studies involving six and 12 patients, respectively, underscoring the need for validation in larger, independent cohorts.

15 October 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YYYuxuan Yang
Yuxuan Yang
HLHuimei Luo
Huimei Luo
HYHuixing Yan
Huixing Yan
HYHaoping Yu
Haoping Yu
XMXinyue Ma
Xinyue Ma
QZQing Zhang
Qing Zhang
Background: POLE -mutated endometrial carcinomas are associated with an excellent prognosis and have become an integral component of the molecular classification of endometrial carcinoma. However, the pathogenicity of many rare non-hotspot POLE exonuclease-domain variants remains uncertain, particularly when they occur in tumors harboring additional molecular alterations that may confound molecular classification. Methods: Histopathologic findings and immunohistochemical expression of mismatch repair proteins and p53 were evaluated. Targeted next-generation sequencing of tumor tissue was performed to characterize genomic alterations, microsatellite instability, tumor mutational burden, and the mutational spectrum. The non-hotspot POLE p.T278K variant was evaluated using the León-Castillo scoring framework. MLH1 promoter methylation was assessed by methylation-specific PCR to further characterize the subclonal MLH1/PMS2 loss. Case summary: A 59-year-old woman with endometrioid endometrial carcinoma underwent total hysterectomy with surgical staging. Targeted next-generation sequencing identified a rare non-hotspot POLE exonuclease-domain variant, c.833C>A (p.T278K), together with two MSH6 frameshift variants, c.3261del (p.F1088Sfs*2) and c.3261dup (p.F1088Lfs*5). The tumor demonstrated an ultramutated genomic profile with a tumor mutational burden of 370.0 mutations/Mb and an MSI-H phenotype. Immunohistochemistry demonstrated subclonal loss of MLH1, PMS2, and MSH6 with retained MSH2 expression; MLH1 promoter methylation was also detected. Conclusion: This case adds clinicopathological and molecular evidence supporting the biological significance of the rare POLE p.T278K variant and illustrates a practical approach for interpreting uncommon POLE exonuclease-domain variants in endometrial carcinomas with multiple molecular classifiers. Accurate identification of the dominant molecular classifier is critical for appropriate molecular classification, prognostic assessment, and clinical management.